Share

Allmed Medical Products Co.,Ltd Stocks

CN¥ 13.77Last Updated 30.04.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.31B

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 13.77
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Allmed Medical Products Co., Ltd engages in the manufacture and sale of wound care and nursing material products in China. The company's general wound care products include elastic and adhesive bandage, oil emulsion, xeroform gauze, woven gauze swabs, fluffy bandages/sponges, abdominal pads, gauze/non-woven drain sponges, post-op sponges, eye pads, cotton filled exodontia sponges, non-stick pads, and petrolatum gauze dressing. It also provides OR/surgery products, including X-ray non-woven swabs, OR towels, laparotomy and neuro sponges, X-ray gauze swabs, and X-ray detectable gauze balls and nonwoven balls; various kits; and patient care products comprising disposable nursing pads and disposable drapes. The company also exports its products. Allmed Medical Products Co., Ltd was founded in 1992 and is based in Shenzhen, the People's Republic of China.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, underpriced on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks